Disease Landscape and Forecast 인사이트
종합적인 시장 정보와 실행 가능한 인사이트를 통해 장기적인 질병 전략을 최적화하세요.
Scleroderma (Systemic Sclerosis) | Treatment Algorithms: Claims Data Analysis | US | 2023
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Methicillin-Resistant Staphylococcus Aureus Infections – Epidemiology – Emerging Markets data
Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
Opioid-Induced Constipation | Treatment Algorithms: Claims Data Analysis | US | 2023
The drug market for opioid-induced constipation (OIC) is served by a variety of prescription medications, including several agents that are approved for irritable bowel syndrome with constipation (…
Idiopathic Pulmonary Fibrosis | Treatment Algorithms: Claims Data Analysis | US | 2023
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by the thickening and stiffening of tissues in the lungs…
Multiple Sclerosis | Unmet Need | Primary-Progressive Multiple Sclerosis | US/EU5 | 2019
Roche/Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS), the first of its kind. According to…
Multiple Sclerosis – Unmet Need – Unmet Need – Primary-Progressive Multiple Sclerosis (US/EU)
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…